| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | 0.0094 | 0.8 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.0099 | 0.8 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0099 | 0.8 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.8 |